Univ Paris-Sud, CNRS, BioCIS-UMR 8076, Laboratoire de Chimie Thérapeutique, LabEx LERMIT, Equipe Labellisée Ligue Contre le Cancer, Faculté de Pharmacie, 5 rue J.-B. Clément, Châtenay-Malabry F-92296, France.
Institut de Chimie des Substances Naturelles, UPR 2301, CNRS avenue de la terrasse, Gif sur Yvette F-91198, France.
Eur J Med Chem. 2014 May 6;78:178-89. doi: 10.1016/j.ejmech.2014.03.032. Epub 2014 Mar 13.
A series of N-methyl-diarylamines 2 was designed and synthesized as a novel class of CA-4 and isoCA-4 analogues. Compounds 2b and 2m showed excellent antiproliferative activity with mean GI50 values at a nanomolar level in a diverse set of human cancer cells. These compounds also inhibited tubulin assembly at a micromolar range, arrested the cellular cycle in the G2/M phase and induced apoptosis at very low concentrations. Preliminary in vitro results revealed that 2b and 2m displayed substantial efficacy as potent antivascular agents. Docking studies indicates that these lead compounds showed a binding mode similar to those observed with isoCA-4 at the colchicine binding site of tubulin.
我们设计并合成了一系列 N-甲基二芳基胺 2,作为新型 CA-4 和异 CA-4 类似物。化合物 2b 和 2m 在一系列不同的人类癌细胞中表现出优异的抗增殖活性,平均 GI50 值达到纳摩尔级。这些化合物还能在微摩尔范围内抑制微管组装,将细胞周期阻滞在 G2/M 期,并在非常低的浓度下诱导细胞凋亡。初步的体外结果表明,2b 和 2m 作为有效的抗血管生成药物具有显著的疗效。对接研究表明,这些先导化合物与异 CA-4 类似,在微管的秋水仙碱结合部位表现出相似的结合模式。